10/31/14 RGEN 25.22 Repligen Corp $RGEN Hit a 52 w
Post# of 44
Posted On: 11/02/2014 2:34:38 AM
10/31/14 RGEN 25.22 Repligen Corp $RGEN Hit a 52 week high of 26.75 Closing the day 10/31/14 at 25.22 -0.27 -1.06% With a day low of 25.15 and a total volume of 530,300.
RGEN Recent Posts: http://investorshangout.com/Repligen-Corp-RGEN-55288/
RGEN Repligen Corp Recent Headline News
Repligen Up 20.3% Since SmarTrend Uptrend Call (RGEN)
Comtex SmarTrend(R) - Thu Oct 30, 9:21AM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on October 6th, 2014 at $20.70. In approximately 3 weeks, Repligen has returned 20.32% as of today's recent price of $24.90.
RGEN: 25.22 (-0.27)
Repligen to Report Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 23, 6:30AM CDT
Repligen Corporation (Nasdaq:RGEN) today announced that it will report third quarter 2014 financial results on Thursday, November 6, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the reporting period ended September 30, 2014.
RGEN: 25.22 (-0.27)
Uptrend Call Working As Repligen Stock Rises 11.6% (RGEN)
Comtex SmarTrend(R) - Wed Oct 22, 5:17PM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on October 6th, 2014 at $20.70. In approximately 2 weeks, Repligen has returned 11.57% as of today's recent price of $23.09.
RGEN: 25.22 (-0.27)
Repligen to Host Investor & Analyst Event on October 16
GlobeNewswire - Fri Oct 10, 10:23AM CDT
- Discussion of Biomanufacturing Trends and Technologies Will be Webcast -
RGEN: 25.22 (-0.27)
Downtrend Call Working As Repligen Stock Falls 12.0% (RGEN)
Comtex SmarTrend(R) - Mon Sep 29, 9:36AM CDT
SmarTrend identified a Downtrend for Repligen (NASDAQ:RGEN) on July 31st, 2014 at $21.57. In approximately 2 months, Repligen has returned 11.99% as of today's recent price of $18.98.
RGEN: 25.22 (-0.27)
Micro Market Monitor: Global Pre-packed Chromatography Columns 2014
M2 - Wed Sep 17, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4xwbt9/micro_market) has announced the addition of the "Micro Market Monitor : Global Pre-packed Chromatography Columns" report to their offering. The pre-packed columns market is one of the fastest-growing segments in the chromatography market. The market was valued at $1.2 billion in 2013, and expected to reach $2.0 billion by 2019, at a CAGR of 8.2% The market is currently restricted by the technological limitations of column size. Large-scale columns (e.g., 45 cm- 60 cm in diameter) are highly commercialized and being developed, thereby increasing the market potential significantly. Pre-packed columns beyond the 30 cm diameter size are generally unavailable. Hence, a sudden surge in demand of columns greater than 45-60 cm in diameter is projected. Larger pre-packed columns are being developed that provide technical, economic, and logistical advantages. There are a myriad of advantages in using pre-packed columns; these are incredibly easy to set up, validate, and clean. Thus, they reduce the amount of labor and time required in their maintenance, increase productivity per run, and offer operational flexibility with rapid changeovers to the users. Once larger, lower-cost, and single-use (or disposable) pre-packed columns are made available for large-scale clinical and commercial applications, this market will increase rapidly. Rising demand for the purification of antibodies, recombinant proteins and vaccines, virus titer reduction validation process development, and external factors are also influencing growth of the pre-packed columns market. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Global Prepacked Columns Market By Type/ Geography 4. Global Prepacked Chromatography Columns Market, By Company Companies Mentioned - Agilent Techlogies - Atoll GmbH - EMD Millipore - GE Lifesciences - Life Techologies (Thermo Fisher Scientific Inc.) - Phenmenex Inc. - Repligen Corp. For more information visit http://www.researchandmarkets.com/research/4x...cro_market
RGEN: 25.22 (-0.27)
Repligen Has Returned 13.0% Since SmarTrend Recommendation (RGEN)
Comtex SmarTrend(R) - Mon Sep 15, 10:59AM CDT
SmarTrend identified a Downtrend for Repligen (NASDAQ:RGEN) on July 31st, 2014 at $21.57. In approximately 2 months, Repligen has returned 13.01% as of today's recent price of $18.76.
RGEN: 25.22 (-0.27)
3 Big-Volume Health Care Stocks in Breakout Territory
at The Street - Thu Sep 04, 5:00AM CDT
These health care stocks rising on unusual volume are within range of triggering breakout trades.
RGEN: 25.22 (-0.27), GMED: 22.17 (+1.27), KTWO: 16.10 (+0.49)
Shares of RGEN Down 11.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Aug 15, 9:28AM CDT
SmarTrend identified a Downtrend for Repligen (NASDAQ:RGEN) on July 31st, 2014 at $21.57. In approximately 2 weeks, Repligen has returned 11.59% as of today's recent price of $19.07.
RGEN: 25.22 (-0.27)
Repligen Reports Second Quarter 2014 Financial Results
GlobeNewswire - Mon Aug 11, 6:07AM CDT
Product Revenue Increases 19.5% to a Record $15.6 Million
RGEN: 25.22 (-0.27)
Repligen Shares Up 42.6% Since SmarTrend's Buy Recommendation (RGEN)
Comtex SmarTrend(R) - Tue Jul 29, 9:12AM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on April 16th, 2014 at $15.18. In approximately 3 months, Repligen has returned 42.62% as of today's recent price of $21.65.
RGEN: 25.22 (-0.27)
Repligen to Report Second Quarter 2014 Financial Results
GlobeNewswire - Mon Jul 28, 6:30AM CDT
Repligen Corporation (Nasdaq:RGEN) today announced that it will report second quarter 2014 financial results on Monday, August 11, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the reporting period ended June 30, 2014.
RGEN: 25.22 (-0.27)
Repligen Up 52.6% Since SmarTrend Uptrend Call (RGEN)
Comtex SmarTrend(R) - Mon Jul 21, 4:42PM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on April 16th, 2014 at $15.18. In approximately 3 months, Repligen has returned 52.57% as of today's recent price of $23.16.
RGEN: 25.22 (-0.27)
Repligen Hires Jon K. Snodgres as Chief Financial Officer
GlobeNewswire - Tue Jul 15, 7:22AM CDT
Repligen Corporation (Nasdaq:RGEN) today announced that Jon K. Snodgres has been named its Chief Financial Officer. Mr. Snodgres joins Repligen from his CFO role at Maquet Cardiovascular, a medical device company. Over the course of five years with Maquet, Mr. Snodgres contributed to the company's growth from niche status to a diversified business generating over $1 billion in annual revenue. Mr. Snodgres previously spent eight years with life sciences company Thermo Fisher Scientific where he was Vice President of Finance for the Laboratory Products Group. At both Maquet and Thermo Fisher, Mr. Snodgres held key responsibility for numerous acquisitions and restructuring programs. He was also integral to the success of pricing and facility optimization programs that drove substantial earnings improvements.
RGEN: 25.22 (-0.27)
Shares of RGEN Up 61.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jul 14, 10:59AM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on April 16th, 2014 at $15.18. In approximately 3 months, Repligen has returned 61.13% as of today's recent price of $24.46.
RGEN: 25.22 (-0.27)
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Jul 02, 12:45PM CDT
I follow a large number of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
RGEN: 25.22 (-0.27), SHPG: 199.80 (+0.38), SLXP: 143.85 (-0.65), DG: 62.67 (+0.22), FDO: 78.29 (+0.47)
Pre-Market Review on Health Care Sector Equities -- Research on Dyax, Repligen, Vanda Pharma, and Ironwood Pharma
PR Newswire - Tue Jul 01, 6:50AM CDT
The US markets on Thursday, June 30, 2014 mostly ended on a lower note as the Dow Jones Industrial Average finished at 16,826.60, down 0.15% and the NASDAQ Composite closed at 4,408.18, up 0.23%. The S&P 500 finished the session 0.04% lower at 1,960.23. During the trading session, five out of ten sectors finished on a negative note. The S&P 500 Health Care Sector Index ended the day at 704.52, down 0.36%, whereas the index has advanced 4.06% in the previous three months. Investor-Edge has initiated coverage on the following equities: Dyax Corp. (NASDAQ: DYAX), Repligen Corp. (NASDAQ: RGEN), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free technical research on DYAX, RGEN, VNDA and IRWD can be downloaded upon signing up at:
RGEN: 25.22 (-0.27), IRWD: 14.02 (-0.15), VNDA: 12.01 (-0.11), DYAX: 12.37 (+0.08)
Shares of RGEN Up 49.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jun 30, 9:08AM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on April 16th, 2014 at $15.18. In approximately 3 months, Repligen has returned 49.67% as of today's recent price of $22.72.
RGEN: 25.22 (-0.27)
RGEN Recent Posts: http://investorshangout.com/Repligen-Corp-RGEN-55288/
RGEN Repligen Corp Recent Headline News
Repligen Up 20.3% Since SmarTrend Uptrend Call (RGEN)
Comtex SmarTrend(R) - Thu Oct 30, 9:21AM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on October 6th, 2014 at $20.70. In approximately 3 weeks, Repligen has returned 20.32% as of today's recent price of $24.90.
RGEN: 25.22 (-0.27)
Repligen to Report Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 23, 6:30AM CDT
Repligen Corporation (Nasdaq:RGEN) today announced that it will report third quarter 2014 financial results on Thursday, November 6, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the reporting period ended September 30, 2014.
RGEN: 25.22 (-0.27)
Uptrend Call Working As Repligen Stock Rises 11.6% (RGEN)
Comtex SmarTrend(R) - Wed Oct 22, 5:17PM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on October 6th, 2014 at $20.70. In approximately 2 weeks, Repligen has returned 11.57% as of today's recent price of $23.09.
RGEN: 25.22 (-0.27)
Repligen to Host Investor & Analyst Event on October 16
GlobeNewswire - Fri Oct 10, 10:23AM CDT
- Discussion of Biomanufacturing Trends and Technologies Will be Webcast -
RGEN: 25.22 (-0.27)
Downtrend Call Working As Repligen Stock Falls 12.0% (RGEN)
Comtex SmarTrend(R) - Mon Sep 29, 9:36AM CDT
SmarTrend identified a Downtrend for Repligen (NASDAQ:RGEN) on July 31st, 2014 at $21.57. In approximately 2 months, Repligen has returned 11.99% as of today's recent price of $18.98.
RGEN: 25.22 (-0.27)
Micro Market Monitor: Global Pre-packed Chromatography Columns 2014
M2 - Wed Sep 17, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4xwbt9/micro_market) has announced the addition of the "Micro Market Monitor : Global Pre-packed Chromatography Columns" report to their offering. The pre-packed columns market is one of the fastest-growing segments in the chromatography market. The market was valued at $1.2 billion in 2013, and expected to reach $2.0 billion by 2019, at a CAGR of 8.2% The market is currently restricted by the technological limitations of column size. Large-scale columns (e.g., 45 cm- 60 cm in diameter) are highly commercialized and being developed, thereby increasing the market potential significantly. Pre-packed columns beyond the 30 cm diameter size are generally unavailable. Hence, a sudden surge in demand of columns greater than 45-60 cm in diameter is projected. Larger pre-packed columns are being developed that provide technical, economic, and logistical advantages. There are a myriad of advantages in using pre-packed columns; these are incredibly easy to set up, validate, and clean. Thus, they reduce the amount of labor and time required in their maintenance, increase productivity per run, and offer operational flexibility with rapid changeovers to the users. Once larger, lower-cost, and single-use (or disposable) pre-packed columns are made available for large-scale clinical and commercial applications, this market will increase rapidly. Rising demand for the purification of antibodies, recombinant proteins and vaccines, virus titer reduction validation process development, and external factors are also influencing growth of the pre-packed columns market. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Global Prepacked Columns Market By Type/ Geography 4. Global Prepacked Chromatography Columns Market, By Company Companies Mentioned - Agilent Techlogies - Atoll GmbH - EMD Millipore - GE Lifesciences - Life Techologies (Thermo Fisher Scientific Inc.) - Phenmenex Inc. - Repligen Corp. For more information visit http://www.researchandmarkets.com/research/4x...cro_market
RGEN: 25.22 (-0.27)
Repligen Has Returned 13.0% Since SmarTrend Recommendation (RGEN)
Comtex SmarTrend(R) - Mon Sep 15, 10:59AM CDT
SmarTrend identified a Downtrend for Repligen (NASDAQ:RGEN) on July 31st, 2014 at $21.57. In approximately 2 months, Repligen has returned 13.01% as of today's recent price of $18.76.
RGEN: 25.22 (-0.27)
3 Big-Volume Health Care Stocks in Breakout Territory
at The Street - Thu Sep 04, 5:00AM CDT
These health care stocks rising on unusual volume are within range of triggering breakout trades.
RGEN: 25.22 (-0.27), GMED: 22.17 (+1.27), KTWO: 16.10 (+0.49)
Shares of RGEN Down 11.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Aug 15, 9:28AM CDT
SmarTrend identified a Downtrend for Repligen (NASDAQ:RGEN) on July 31st, 2014 at $21.57. In approximately 2 weeks, Repligen has returned 11.59% as of today's recent price of $19.07.
RGEN: 25.22 (-0.27)
Repligen Reports Second Quarter 2014 Financial Results
GlobeNewswire - Mon Aug 11, 6:07AM CDT
Product Revenue Increases 19.5% to a Record $15.6 Million
RGEN: 25.22 (-0.27)
Repligen Shares Up 42.6% Since SmarTrend's Buy Recommendation (RGEN)
Comtex SmarTrend(R) - Tue Jul 29, 9:12AM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on April 16th, 2014 at $15.18. In approximately 3 months, Repligen has returned 42.62% as of today's recent price of $21.65.
RGEN: 25.22 (-0.27)
Repligen to Report Second Quarter 2014 Financial Results
GlobeNewswire - Mon Jul 28, 6:30AM CDT
Repligen Corporation (Nasdaq:RGEN) today announced that it will report second quarter 2014 financial results on Monday, August 11, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the reporting period ended June 30, 2014.
RGEN: 25.22 (-0.27)
Repligen Up 52.6% Since SmarTrend Uptrend Call (RGEN)
Comtex SmarTrend(R) - Mon Jul 21, 4:42PM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on April 16th, 2014 at $15.18. In approximately 3 months, Repligen has returned 52.57% as of today's recent price of $23.16.
RGEN: 25.22 (-0.27)
Repligen Hires Jon K. Snodgres as Chief Financial Officer
GlobeNewswire - Tue Jul 15, 7:22AM CDT
Repligen Corporation (Nasdaq:RGEN) today announced that Jon K. Snodgres has been named its Chief Financial Officer. Mr. Snodgres joins Repligen from his CFO role at Maquet Cardiovascular, a medical device company. Over the course of five years with Maquet, Mr. Snodgres contributed to the company's growth from niche status to a diversified business generating over $1 billion in annual revenue. Mr. Snodgres previously spent eight years with life sciences company Thermo Fisher Scientific where he was Vice President of Finance for the Laboratory Products Group. At both Maquet and Thermo Fisher, Mr. Snodgres held key responsibility for numerous acquisitions and restructuring programs. He was also integral to the success of pricing and facility optimization programs that drove substantial earnings improvements.
RGEN: 25.22 (-0.27)
Shares of RGEN Up 61.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jul 14, 10:59AM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on April 16th, 2014 at $15.18. In approximately 3 months, Repligen has returned 61.13% as of today's recent price of $24.46.
RGEN: 25.22 (-0.27)
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Jul 02, 12:45PM CDT
I follow a large number of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
RGEN: 25.22 (-0.27), SHPG: 199.80 (+0.38), SLXP: 143.85 (-0.65), DG: 62.67 (+0.22), FDO: 78.29 (+0.47)
Pre-Market Review on Health Care Sector Equities -- Research on Dyax, Repligen, Vanda Pharma, and Ironwood Pharma
PR Newswire - Tue Jul 01, 6:50AM CDT
The US markets on Thursday, June 30, 2014 mostly ended on a lower note as the Dow Jones Industrial Average finished at 16,826.60, down 0.15% and the NASDAQ Composite closed at 4,408.18, up 0.23%. The S&P 500 finished the session 0.04% lower at 1,960.23. During the trading session, five out of ten sectors finished on a negative note. The S&P 500 Health Care Sector Index ended the day at 704.52, down 0.36%, whereas the index has advanced 4.06% in the previous three months. Investor-Edge has initiated coverage on the following equities: Dyax Corp. (NASDAQ: DYAX), Repligen Corp. (NASDAQ: RGEN), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free technical research on DYAX, RGEN, VNDA and IRWD can be downloaded upon signing up at:
RGEN: 25.22 (-0.27), IRWD: 14.02 (-0.15), VNDA: 12.01 (-0.11), DYAX: 12.37 (+0.08)
Shares of RGEN Up 49.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jun 30, 9:08AM CDT
SmarTrend identified an Uptrend for Repligen (NASDAQ:RGEN) on April 16th, 2014 at $15.18. In approximately 3 months, Repligen has returned 49.67% as of today's recent price of $22.72.
RGEN: 25.22 (-0.27)
(0)
(0)Repligen Corporation (RGEN) Stock Research Links
Scroll down for more posts ▼